| Literature DB >> 23597562 |
Françoise Bono1, Frederik De Smet, Corentin Herbert, Katrien De Bock, Maria Georgiadou, Pierre Fons, Marc Tjwa, Chantal Alcouffe, Annelii Ny, Marc Bianciotto, Bart Jonckx, Masahiro Murakami, Anthony A Lanahan, Christof Michielsen, David Sibrac, Frédérique Dol-Gleizes, Massimiliano Mazzone, Serena Zacchigna, Jean-Pascal Herault, Christian Fischer, Patrice Rigon, Carmen Ruiz de Almodovar, Filip Claes, Isabelle Blanc, Koen Poesen, Jie Zhang, Inmaculada Segura, Geneviève Gueguen, Marie-Françoise Bordes, Diether Lambrechts, Roselyne Broussy, Marlies van de Wouwer, Corinne Michaux, Toru Shimada, Isabelle Jean, Silvia Blacher, Agnès Noel, Patrick Motte, Eran Rom, Jean-Marie Rakic, Susumu Katsuma, Paul Schaeffer, Avner Yayon, Ann Van Schepdael, Harald Schwalbe, Francesco Luigi Gervasio, Geert Carmeliet, Jef Rozensky, Mieke Dewerchin, Michael Simons, Arthur Christopoulos, Jean-Marc Herbert, Peter Carmeliet.
Abstract
Receptor tyrosine kinases (RTK) are targets for anticancer drug development. To date, only RTK inhibitors that block orthosteric binding of ligands and substrates have been developed. Here, we report the pharmacologic characterization of the chemical SSR128129E (SSR), which inhibits fibroblast growth factor receptor (FGFR) signaling by binding to the extracellular FGFR domain without affecting orthosteric FGF binding. SSR exhibits allosteric properties, including probe dependence, signaling bias, and ceiling effects. Inhibition by SSR is highly conserved throughout the animal kingdom. Oral delivery of SSR inhibits arthritis and tumors that are relatively refractory to anti-vascular endothelial growth factor receptor-2 antibodies. Thus, orally-active extracellularly acting small-molecule modulators of RTKs with allosteric properties can be developed and may offer opportunities to improve anticancer treatment.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23597562 DOI： 10.1016/j.ccr.2013.02.019
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743